First Turn Management LLC Makes New $13.20 Million Investment in Repligen Co. (NASDAQ:RGEN)

First Turn Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 88,714 shares of the biotechnology company’s stock, valued at approximately $13,202,000. Repligen comprises 2.1% of First Turn Management LLC’s investment portfolio, making the stock its 29th biggest holding. First Turn Management LLC owned about 0.16% of Repligen as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Swedbank AB bought a new stake in shares of Repligen in the 1st quarter valued at $5,518,000. Banque Pictet & Cie SA grew its position in Repligen by 74.6% in the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after purchasing an additional 14,746 shares during the period. Vanguard Group Inc. grew its position in Repligen by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after purchasing an additional 21,719 shares during the period. Diversified Trust Co grew its position in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 106 shares during the period. Finally, Thrivent Financial for Lutherans grew its position in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after purchasing an additional 425,061 shares during the period. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RGEN. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday, November 13th. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

RGEN opened at $123.41 on Tuesday. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of -333.53, a P/E/G ratio of 3.75 and a beta of 0.96. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm’s fifty day moving average price is $141.09 and its two-hundred day moving average price is $144.24.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.23 EPS. As a group, analysts anticipate that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.